Please ensure Javascript is enabled for purposes of website accessibility

Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street

By George Budwell - Oct 24, 2014 at 9:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bristol-Myers Squibb reported third-quarter earnings this morning. Here's what you need to know.

Bristol-Myers Squibb (BMY 1.59%) posted its third-quarter earnings this morning before the bell, beating consensus on both earnings per share and revenue. Specifically, the company reported GAAP EPS of $0.43 for the quarter, compared to the Street's estimate of $0.42. Revenue came in at $3.92 billion for the three month period, topping consensus by $12 million. Bristol also lowered its 2014 GAAP EPS guidance to $1.15-$1.25, down from $1.50-$1.60, presumably due to higher than expected research and development costs.  

Despite these rosy quarterly numbers, Bristol still saw revenue drop by 4% year-over-year, reflecting the loss of exclusivity for former top selling drugs like the blood thinner Plavix and the divestiture of its diabetes franchise to AstraZeneca (AZN 1.01%). On a GAAP basis, EPS edged higher by 2% relative to a year ago, mostly due to the company's widespread restructuring efforts in the wake of the patent cliff.

Top-line is being held steady by newer drugs
A deeper look at today's report shows that most of Bristol's strong revenue performance during the quarter can be attributed to handful of newer drugs, namely Yervoy, Sprycel, Orencia, and Eliquis. For example, the company's skin cancer drug, Yervoy, saw sales grow by 47% to $350 million, relative to the same period a year ago. Sprycel sales also jumped by 22% to $385 million during the quarter.

What's key to understand is that the double digit sales growth of these next generation drugs did more than simply offset the marked decline in former stars like Abilify, which saw sales drop by a whopping 21% during quarter. If its diabetes alliance with AstraZeneca is excluded, for instance, we can see that Bristol's revenue actually grew by 7% year-over-year. 

New drug launches should help to further boost its top-line soon
Putting this quarter's sales numbers aside for the moment, Bristol's management was quick to point out that its PD-1 inhibitor, Opdivo, and its hepatitis C dual regimen of Daklinza and Sunvepra should help to return the company to growth in the near future. Presently, Opdivo is under regulatory review for advanced melanoma, and the company's hepatitis C regimen has been launched in Japan and several countries within the EU.  

Even so, I think it's best to take a skeptical view of both of these products for the time being. Opdivo would initially be approved for an indication that is stacked with new drugs, making it hard to carve out a profitable niche. Moreover, Bristol decided not to launch its hepatitis C regimen in the U.S. following the approval of Gilead Sciences' (GILD 0.24%) fixed dose combo pill Harvoni earlier this month. In short, these two products look like they have limited upside because of these issues, at least for the moment.    

What to watch
Bristol is in a battle with its Big Pharma competitors to gain market share in the next round of "game-changing" drugs, such as PD-1 inhibitors and so-called "terminator" hep C treatments. At present, it looks like it lost the first round to Gilead in the hep C arena, putting a heavier focus on Opdivo to perform well. Nonetheless, Opdivo is in a tight race with Merck's (MRK 0.74%) competing PD-1 inhibitor, Keytruda, to gain market share. Put simply, this is a pivotal issue for investors to keep a close watch on going forward.  

 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.08 (0.74%) $0.68
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$65.34 (0.24%) $0.16
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.33 (1.59%) $1.18
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.17 (1.01%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.